Eli Lilly & Co. vs Pfizer Inc.
LLY vs PFE — side-by-side comparison from reported financials. LLY leads 10, PFE leads 2 of 12 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
| Metric | LLY | PFE |
|---|---|---|
| Price | $1 177.20 | $28.27 |
| Market cap | $1.05T | $161B |
| Revenue (TTM) | $79.7B | $63.7B |
| Revenue growth | +31.7% | -14.8% |
| Net margin | 33.5% | 6.8% |
| Free cash flow | $18.2B | $11.0B |
| Net cash (debt) | ($35.2B) | ($51.6B) |
| 1-year price return | +37.6% | +12.0% |
| P/E | 41.6 | 37.2 |
| P/E vs own history (cheap-side %) | 88% | 4% |
| Dividend yield | 0.52% | 6.07% |
| Return on equity | 93% | 5% |
| Altman Z-score | 7.10 | 1.96 |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 50,000 | 75,000 |
Full résumé-style profiles: LLY CV · PFE CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.